Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS
Corvus Pharmaceuticals — Technical Presentation (December 2020)
13 slides from Corvus Pharmaceuticals's technical presentation, Dec 5, 2020
Slide 1: The ITK Inhibitor CPI-818 Blocks Activation of T Cells from ALPS Patients
The ITK Inhibitor CPI-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and is Active in a Murine Model of ALPS V Koneti Rao, MD Laboratory of Clinical Immunology and Microbiology, NIAID, NIH Session 203, Presentation Number 95, Dec 5th, 2020
Slide 2: The ITK Inhibitor CPI-818 Blocks Activation of T Cells from ALPS Patients; Disclosures
The ITK Inhibitor CPI-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and is Active in a Murine Model of ALPS V Koneti Rao, MD Laboratory of Clinical Immunology and Microbiology, NIAID, NIH V Koneti Rao2, Patrick P Ng1, Craig M Hill1, Richard A Miller1,
Slide 3: ALPS was recognized as a distinct entity in NIAID-NIH in 1990s
ALPS was recognized as a distinct entity in NIAID-NIH in 1990s Autoimmune Lymphoproliferative Syndrome (ALPS) • FAS mediated disorder of lymphocyte apoptosis leads to lymphocyte accumulation • Pathophysiology is driven by germline and somatic heterozygous variants in FAS • Leads to childhood onset l
Slide 4: Evolving paradigms of management of B cell driven pathobiology due to T cell dysfunction in ALPS
Evolving paradigms of management of B cell driven pathobiology due to T cell dysfunction in ALPS: 1990s - 2020 • Since 1993, 220 ALPS-FAS patients and more than 400 families with ALPS like disorders with non-malignant lymphoproliferation have been followed at NIH ALPS Clinic as part of family-studie
Slide 5: FAS and T cell receptor (TCR) signaling are linked
FAS and T cell receptor (TCR) signaling are linked T cells • TCR and FAS pathways modulate an equilibrium between proliferation and activation- induced cell death • ITK is a key enzyme in the TCR pathway and provides a convenient drug target • Hypotheses – Dysregulated growth of Fas- deficient T cel
Slide 6: ITK is expressed similarly in both normal and ALPS T cells
ITK is expressed similarly in both normal and ALPS T cells Healthy donor ALPS patient #1 ALPS patient #2 B cells (negative) CD4+ T cells CD8+ T cells CD4- CD8- T cells ITK expression pattern is similar in PBMCs from ALPS patients compared to a healthy donor ITK detected in CD4+, CD8+, and double-neg
Slide 7: CPI-818: a selective and irreversible inhibitor of ITK in Phase I clinical development
CPI-818: a selective and irreversible inhibitor of ITK in Phase I clinical development CPI-818 selectively inhibits ITK – Covalent mechanism, targets cysteine at active site – Similar mechanism to BTK inhibitor, ibrutinib CPI-818 in a Ph I study in T cell lymphoma – Oral administration, BID Dosing C
Slide 8: CPI-818 inhibits activation of stimulated T cells in ALPS patients
CPI-818 inhibits activation of stimulated T cells in ALPS patients Healthy donor TCR stimulation (anti-CD3/CD28) led to activation of T cells (CD25) in healthy donor and one of two ALPS patients ALPS patient #1 CD25 expression was fully blocked by ITK inhibition with CPI-818 CPI-818 was not cytotoxi
Slide 9: CPI-818 inhibits T cell activation-induced cell death
CPI-818 inhibits T cell activation-induced cell death Healthy donor PBMCs from healthy donor and one of two ALPS patients could elicit AICD ALPS patient #1 ITK inhibition by CPI-818 – Blocked AICD – Did not induce apoptosis in ALPS patient #2 unstimulated cells Unstimulated Unstimulated + CPI-818 St
Slide 10: Evaluation of CPI-818 in Fas-deficient mice (MRL/lpr-/-): Study 1
Evaluation of CPI-818 in Fas-deficient mice (MRL/lpr-/-) CPI-818 inhibits lymphadenopathy and proteinuria in lpr mice (STUDY 1) Fas-deficient (lpr) mice considered an in vivo model of ALPS - Expansion of double-negative (CD4−CD8−B220+) T cells, Massive lymphadenopathy, Autoimmune manifestations Kidn
Slide 11: CPI-818 selectively inhibits CD4-CD8- DN T cell expansion in the spleen
CPI-818 selectively inhibits CD4-CD8- DN T cell expansion in the spleen and restored normal proportion of B and NK cells Autoreactive (CD4-CD8- B220+) Absolute CD4- CD8- B220+ Cell Count TotalCD4 Absolute CD4 + + cells count Absolute B Cell Count Absolute NK Cell Count 1500 400 150 Total B cells 15
Slide 12: STUDY 2: CPI-818 reduced established disease in MRL/lpr
STUDY 2: CPI-818 reduced established disease in MRL/lpr Treatment began after lymphadenopathy Lymphadenopathy Score Skin Lesion Score Proteinuria Control Diet Control Diet Control Diet Cyclophosphamide Cyclophosphamide Cyclophosphamide CPI-818 Diet CPI-818 Diet CPI-818 Diet Age (Weeks) CPI-818 treat
Slide 13: Conclusions
Conclusions • Clinical stage covalent ITK inhibitor CPI-818 in ALPS patient PBMCs – Was not cytotoxic – Inhibited T cell activation (CD25/CD69) – Inhibited activation-induced cell death • In Fas-deficient (MRL/lpr-/-) mice – CPI-818 selectively inhibited the expansion of double-negative T cells – Re
Corvus Pharmaceuticals — Technical Presentation (December 2020) on 6ix